This company listing is no longer active
IPA Stock Overview
A biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ImmunoPrecise Antibodies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$6.50 |
| 52 Week High | CA$8.81 |
| 52 Week Low | CA$4.52 |
| Beta | 0.30 |
| 11 Month Change | -3.70% |
| 3 Month Change | -16.77% |
| 1 Year Change | -23.26% |
| 33 Year Change | 103.13% |
| 5 Year Change | 160.00% |
| Change since IPO | 0.77% |
Recent News & Updates
Shareholder Returns
| IPA | CA Life Sciences | CA Market | |
|---|---|---|---|
| 7D | -6.5% | 0.1% | 1.7% |
| 1Y | -23.3% | 19.6% | 23.7% |
Return vs Industry: IPA exceeded the Canadian Life Sciences industry which returned -28.3% over the past year.
Return vs Market: IPA underperformed the Canadian Market which returned -1.4% over the past year.
Price Volatility
| IPA volatility | |
|---|---|
| IPA Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.9% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: IPA's share price has been volatile over the past 3 months.
Volatility Over Time: IPA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 85 | Jennifer Bath | www.ipatherapeutics.com |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.
ImmunoPrecise Antibodies Ltd. Fundamentals Summary
| IPA fundamental statistics | |
|---|---|
| Market cap | CA$162.08m |
| Earnings (TTM) | -CA$22.86m |
| Revenue (TTM) | CA$19.47m |
8.3x
P/S Ratio-7.1x
P/E RatioIs IPA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPA income statement (TTM) | |
|---|---|
| Revenue | CA$19.47m |
| Cost of Revenue | CA$8.70m |
| Gross Profit | CA$10.76m |
| Other Expenses | CA$33.62m |
| Earnings | -CA$22.86m |
Last Reported Earnings
Jul 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 55.29% |
| Net Profit Margin | -117.44% |
| Debt/Equity Ratio | 0% |
How did IPA perform over the long term?
See historical performance and comparison